Adeno-associated virus (AAV) is currently one of the most promising systems for human gene therapy. Numerous preclinical studies have documented the excellent safety profile of these vectors along ...

A recombination between the short homologous regions of nucleotide sequences in the retroviral vector and packaging cell line has been thought to be a major cause of the production of ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...

Gene and modified cell therapies (for example, chimeric antigen receptor [CAR] T-cell therapies) in early to late clinical development are showing significant promise to treat and potentially cure ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

First look at ReiCell-AAV next week at Advanced Therapies London, Booth 94 With three cutting-edge platforms for gene therapy and genetic vaccine production, ReiThera remains unique among CDMOs Rome, ...